2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2926

Rorc Positive Th17, Th17/Th1, and Th17.1 Cells from the Blood of Treatment NaïVe RA Patients Differ in IL-17A but Are All Pathogenic When Co-Cultured with RA Synovial Fibroblasts
Abstract Number: 2152

S100A11 Protein Is Increased in Rheumatoid Arthritis and Is Associated with Disease Activity and Inflammation
Abstract Number: 172

S100A8/A9 Produced during Experimental Osteoarthritis Induces a Systemic Decrease in BM Monocytes and Increases Ly6C High Monocytes Locally in the Joint
Abstract Number: 173

S100A8/A9, a Potent Serum and Molecular Imaging Biomarker for Synovial Inflammation and Joint Destruction in Seronegative Experimental Arthritis
Abstract Number: 1613

Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis
Abstract Number: 392

Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Abstract Number: 3009

Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 2896

Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers
Abstract Number: 958

Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Abstract Number: 1590

Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 3247

Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Abstract Number: 687

Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 211

Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia
Abstract Number: 1622

Safety and Efficacy of Iguratimod in Patients with Active Rheumatoid Arthritis: A Multicenter, Single-Arm, Open-Label, Real World Study
Abstract Number: 1043

Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].